

Researchers at Japanese universities have contributed to drug discovery

Compound	Contributor	Developer	Approved*	Indication
Ivermectin [Stromectol ®]	Dr. Satoshi Omura at The Kitasato Institutes	Merck	1992 [Fr.] 2002	Antiparasitic medicine
Tacrolimus [Prograf ®]	Dr. Takenori Ochiai at Chiba Univ.	Astellas	1993	Immunosuppression
Oxaliplatin [Elplat ®]	Dr. Yoshinori Kidani at Nagoya City Univ.	Debiopharm [Switzerland]	1980's [Fr.] 2005	Colon or rectal cancer (licensed-out to Yakult)
Tocilizumab [Actemra ®]	Dr. Chuzo Kishimoto at Osaka Univ.	Chugai	2007	Rheumatoid arthritis
Fingolimod [Gilenya ®]	Dr. Tetsuro Fujita at Kyoto Univ.	Mitsubishi Tanabe	2010	Multiple sclerosis (licensed-out to Novartis)
Eribulin [Halaven ®]	Dr. Yoshimasa Hirata at Nagoya Univ.	Eisai	2010 [FDA]	treating late-stage breast cancer (derived from Halichondrin B in a black sponge found off the coast of Kanagawa Prefecture's Miura.)
Dolutegravir [TIVICAY ®]	Dr. Yorio Hinuma at Kyoto Univ.	Shionogi	2013	Next Generation HIV Integrase Inhibitor
Crizotinib [XALKORI ®]	Dr. Hiroyuki Mano at Jichi Medical Univ.	Pfizer	2012	<i>EML4-ALK</i> positive advanced non-small cell lung cancer(NSCLC)
Nivolumab [OPDIVO ®]	Dr. Tasuku Honjo at Kyoto Univ.	Ono	2014	anti-human PD-1 monoclonal antibody; unresectable malignant melanoma

* Year of being approved in Japan unless stated

Source: Drug Interview Form, etc.